Are you Dr. Matushansky?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 65 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
161 Fort Washington Ave
New York, NY 10032Phone+1 646-317-6041Fax+1 212-305-6891- Is this information wrong?
Summary
- Dr. Igor Matushansky, MD is an oncologist in New York, New York. He is currently licensed to practice medicine in New York. He is affiliated with New York-Presbyterian Hospital and is an Assistant Professor at Columbia University College of Phys & Surg.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2003
Albert Einstein College of MedicineClass of 2001
Certifications & Licensure
NY State Medical License 2003 - 2026
Clinical Trials
- A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients Start of enrollment: 2018 Dec 12
- A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers Start of enrollment: 2019 Dec 11
Publications & Presentations
PubMed
- 6 citationsDevelopment and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform.Henning Lauterbach, Sarah Schmidt, Kia Katchar, Xiaoping Qing, Corinne Iacobucci, Andy Hwang, Katia Schlienger, Ursula Berka, Josipa Raguz, Sarah M. Ahmadi-Erber, Timo...> ;Frontiers in Oncology. 2021 Oct 14
- 7 citationsLive-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancerSarah Schmidt, Weldy V. Bonilla, Andrea Reiter, Felix Stemeseder, Theresa Kleissner, Daniel Oeler, Ursula Berka, Ahmed El-Gazzar, Bettina Kiefmann, Sophie Schulha, Jos...> ;Oncoimmunology. 2020 Sep 15
- 101 citationsTerminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.Xi Zhang, Filemon S. Dela Cruz, Melissa Terry, Fabrizio Remotti, Igor Matushansky> ;Oncogene. 2013 May 2
- Join now to see all
Press Mentions
HOOKIPA and DarwinHealth Enter into a Research Collaboration and License Agreement to Discover and Prioritize Novel Immunogenic, Tumor-Specific Cryptic AntigensNovember 28th, 2018
Crescendo Names Ex-Roche Leader Pisa as CMOSeptember 11th, 2018
Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa BiotechMarch 6th, 2017
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York
